Left Atrial Geometry and Phasic Function Determined by Cardiac Magnetic Resonance Are Independent Predictors for Outcome in Non-Ischaemic Dilated Cardiomyopathy

Bianca Olivia Cojan-Minzat1,2, Alexandru Zlibut1, Ioana Danuta Muresan1, Rares-Ilie Orzan1, Carmen Cionca3, Dalma Horvat1, Liliana David1,4, Alexandru Ciprian Visan5*, Mira Florea2 and Lucia Agoston-Coldea1,3,4,*

Abstract: Left atrial (LA) geometry and phasic functions are frequently impaired in non-ischaemic dilated cardiomyopathy (NIDCM). Cardiac magnetic resonance (CMR) can accurately measure LA function and geometry parameters. We sought to investigate their prognostic role in patients with NIDCM. We prospectively examined 212 patients with NIDCM (49 ± 14.2-year-old; 73.5% males) and 106 healthy controls. LA volumes, phasic functions, geometry, and fibrosis were determined using CMR. A composite outcome (cardiac death, ventricular tachyarrhythmias, heart failure hospitalization) was ascertained over a median of 26 months. LA phasic functions, sphericity index (LASI) and late gadolinium enhancement (LA-LGE) were considerably impaired in the diseased group (p < 0.001) and significantly correlated with impaired LV function parameters (p < 0.0001). After multivariate analysis, LA volumes, LASI, LA total strain (LA-εt) and LA-LGE were associated with increased risk of composite outcome (p < 0.001). Kaplan–Meier analysis showed significantly higher risk of composite endpoint for LA volumes (all p < 0.01), LASI > 0.725 (p < 0.003), and LA-εt < 30% (p < 0.0001). Stepwise Cox proportional-hazards models demonstrated a considerable incremental predictive value which resulted by adding LASI to LA-εt (Chi-square = 10.2, p < 0.001), and afterwards LA-LGE (Chi-Square = 15.8; p < 0.0001). NIDCM patients with defective LA volumes, LASI, LA-LGE and LA-εt had a higher risk for an outcome. LA-εt, LASI and LA-LGE provided independent incremental predictive value for outcome.

Keywords: non-ischaemic dilated cardiomyopathy; cardiac magnetic resonance imaging; left atrial phasic function; left atrial volumes; left atrial sphericity index; left atrial strain

1. Introduction

Non-ischemic dilated cardiomyopathy (NIDCM) is the commonest primary myocardial disorder, being characterized by systolic dysfunction due to left (LV) or bi-ventricular dilation, in the absence of coronary syndromes, arterial hypertension (AHT) or valvular heart disease (VHD) [1]. LA function is a key factor in maintaining LV haemodynamics. It is regularly impaired in various cardiac diseases and is strongly associated with mortality and poor outcomes [2,3]. Cardiac magnetic resonance imaging (CMR) is an advanced cardiovascular imaging technique that pledges to accurately characterize LA function and...
geometry, but studies which evaluate their predictive ability are still scarce, especially in NIDCM [4].

The interdependency between the LA and LV functions is widely recognized [5]. LA function is characterized by an unceasing physiological process which can be divided into three successive phases: LA reservoir function (LA filling in late LV systole), conduit function (passive LV filling in early diastole) and booster pump function (active LV filling in late diastole). Eventually, a LA suction force emerges which actively fills the LA in early LV systole [4,6]. Through this phasic phenomenon, LA has a central role in maintaining cardiac output even when the LV relaxation and compliance are defective [7]. In turn, the progression of LV diastolic dysfunction and increased filling pressures are key factors in promoting LA impairment and enlargement [5].

Late advances in the field of CMR have granted proper description of LA function and, thus, deploying specific parameters. These have comparable accuracy with speckle-tracking echocardiography in terms of LA strain and phasic function evaluation [8,9]. LA phasic functions were associated with the progression of heart failure (HF), LV diastolic dysfunction and increased filling pressures [10], and were independent predictors of major adverse cardiovascular events (MACEs) [11]. Moreover, LA strain parameters determined by CMR were able to distinguish patients with impaired LV relaxation from those without it [12]. However, their predictive roles in patients with NIDCM are still uncharted.

In most cardiac conditions, altered LA geometry is strongly associated with cardiac dysfunction [13]. Maximum indexed LA volume (LAV_max) is significantly correlated with MACEs, and current international guidelines recommend it as a marker of diastolic dysfunction [14,15], being also associated with increased mortality [16,17]. Moreover, LA sphericity index (LASI) is a novel marker that characterizes LA’s shape and remodelling which might play important roles in outcome prediction, but studies are just in their infancy [18]. LASI was able to predict the recurrence of atrial fibrillation [19] and HF hospitalization in NIDCM [20].

The aim of our study was to evaluate the role of LA geometry and function in the diagnosis and prognosis prediction in patients with NIDCM using CMR.

2. Materials and Methods

2.1. Study Design and Patients’ Characteristics

We conducted a prospective study on 212 patients with NIDCM and 106 healthy volunteers who were examined in the 2nd Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy from October 2017 to November 2020. The inclusion criteria comprised: (1) impaired LV ejection fraction (LVEF) ≤ 45%; (2) LV chamber dilation with indexed LV end-diastolic volume (LVEDV) ≥ 97 mL/m^2; both being CMR-determined [1]. The exclusion criteria comprised: (1) ischemic heart disease which was defined as >50% angiographical stenosis in any epicardial coronary artery. Primary valvular disease was defined as moderate or higher valvular stenosis or regurgitation, apart from functional ones. Functional mitral regurgitation was defined as mitral regurgitation secondary to left ventricular remodeling resulting in failure of leaflet coaptation, in the setting of normal mitral valve anatomy, on echocardiography and CMR; (2) contraindications to CMR (incompatible metallic devices, significant chronic renal failure with estimated glomerular filtration rate < 30 mL/min/1.73 m^2, or claustrophobia); (3) refusal to participate in the study (Figure 1). A total of 106 subjects free of overt cardiovascular disease, normal electrocardiogram, echocardiogram and negative CMR served as the control group.

Each patient underwent the same investigation protocol, including medical history, physical examination, 12-lead electrocardiogram, 24-h Holter monitoring, biochemical analysis, standard echocardiography and CMR.
Figure 1. Flow chart detailing the study cohort. Abbreviations: CMR, cardiac magnetic resonance imaging; LGE, late gadolinium enhancement; NIDCM, nonischemic dilated cardiomyopathy.

2.2. CMR Imaging

All CMR images were ECG-gated and were acquired during apnoea with a 1.5 T Open Bore system MR scanner (Magnetom Altea, Siemens Medical Solutions, Erlangen, Germany). A standard scanning protocol in compliance with current international guidelines was used [21]. The acquisition of fast imaging employing steady-state free precession (SSFP) sequences was performed to detect ventricular function and mass in conventional cardiac short-axis and long-axis planes, to enclose both ventricles from base to apex. S-
quence parameters SSFP were as follows: repetition time (TR) 3.6 ms; echo time (TE) 1.8 ms; flip angle 60°; slice thickness 6 mm; field of view 360 mm; image matrix of 192 × 192 pixels; voxel size 1.9 × 1.9 × 6 mm; 25–40 ms temporal resolution reconstructed to 25 cardiac phases.

Late gadolinium enhancement (LGE) imaging, with sequence parameters of TR 4.8 ms, TE 1.3 ms, and inversion time 200–300 ms, was performed to detect myocardial fibrosis acquired 10 min after intravenous infusion of 0.2 mmol/kg gadoxetic acid (Clariscan, GH Healthcare AS, Oslo, Norway) in long- and short-axis views, using a segmented inversion-recovery gradient-echo sequence. Inversion time was adjusted to optimize nulling of apparently normal myocardium. Brachial blood pressure was continuously monitored during SSFP-CMR acquisitions.

Transmitral inflow and myocardial velocity ECG-gated phase-contrast CMR (PC-CMR) pulse sequences were used to acquire two series of images during two consecutive breath-holds, at the tips of the mitral leaflets, perpendicular to the transmitral inflow: (1) transmitral through-plane flow velocity (encoding velocity Venc = 180 cm/s, TE = 3.1 ms, TR = 7.6 ms, views per segment = 2; temporal resolution = 15 ms), and (2) longitudinal myocardial velocity (Venc = 15 cm/s or 20 cm/s, TE = 5 ms, TR = 9.5 ms, views per segment = 2; temporal resolution = 20 ms). For both sequences, the following parameters were used: flip angle = 20°, slice thickness = 8 mm, pixel spacing = 1.9 mm × 1.9 mm, matrix 256 × 128. To minimize background offsets and for the acquisition time to remain compatible with breath-holding, a 50% rectangular field-of-view was used [22]. Each dataset included dynamic modulus series (providing information about the variation in mitral valve orifice geometry during the cardiac cycle) and the associated velocity-encoded dynamic series, which were acquired during a complete cardiac cycle. These contours were then superimposed on velocity PC-CMR images for flow analysis.

2.3. CMR Analysis

2.3.1. Quantitative Assessment of the LV Functions

All images were evaluated by two experienced observers, blinded to all clinical data. LVEDV and LV end-systolic volume (LVESV), LVEF and LV mass (LVM) were measured on short-axis cine-SSFP images. Epicardial and endocardial borders were traced semi-automatically at end-diastole and end-systole using specialized software (Syngo.Via VB20A_HF04, Argus, Siemens Medical Solutions). All volumes were indexed to body surface area. The LV sphericity index (LVSI) was calculated by dividing LVEDV by the volume of a sphere whose LV length (L) was measured at the end of diastole: LVSI = LVEDV/[π/6 × (L)3] [23].

LGE was assessed from short-axis images, using the 17-segments model [24] and was quantified using a signal intensity threshold of >5SD above a remote reference for normal myocardium, as recommended by international protocols [25], using dedicated software (cvi42, Circle Cardiovascular Imaging Inc., Calgary, CA, USA).

Applying the previously described algorithms, three basic waveforms were obtained, which allowed measurements of the following parameters using dedicated software (cvi42, Circle Cardiovascular Imaging Inc., Calgary, CA, USA): transmitral early (E, in cm/s) and late (A, in cm/s) peak velocities and early (EQ, in mL/s) and late (AQ, in mL/s) peak flow-rates. Transmitral filling volume (FV), which was estimated as the area under the trans-mitral and flow-rate curve between the automatically detected beginning and end of the filling period; transmitral deceleration time (DT, ms) and isovolumic relaxation time (IVRT, ms) were also determined. Myocardial longitudinal early (E’, in cm/s) and late (A’, in cm/s) peak velocity on LV lateral wall. Of note, the same dataset used for transmitral flow analysis was used to extract aortic ejection flow-rate curves and to identify the end of ejection time, which was used for IVRT estimation.
2.3.2. Quantitative Assessment LA Volume and Function

LA volumes (LAV) were measured at different moments of the cardiac cycle: maximum LA volume at LV end-systole, just before mitral valve opening (LAV_{max}), pre-atrial contraction LA volume (LAV_{preA}) at LV diastole immediately prior to LA contraction, and minimum LA volume at mitral valve closure and late LV diastole after LA contraction (LAV_{min}). Each phase was visually determined and LA volumes were calculated using apical 4- and 2-chamber views. In the 4-chamber view, the LA border started from the medial side of the mitral annulus, included interatrial septum, posterior, and lateral LA walls and ended at the lateral mitral annulus. In the 2-chamber view, the analyzed LA border started from anterior mitral annulus and continued over the LA roof, the posterior wall, and the floor of the LA and ended at the inferior mitral annulus. LA length was the long-axis length of LA from each chamber. The LA endocardial border was manually delineated using both the 2-and 4-chamber cine images, although pulmonary veins confluence and LA appendage were excluded. The LAV was calculated using this formula: LA volume = (0.848 × area 4-chamber × area 2-chamber)/([length 4-chamber + length 2-chamber]/2) [6,26]. LASI was calculated using this formula: LA volume = maximum LA volume/(4π/3)(maximum LA length/2) [19]. In all patients, LAV was indexed to body surface. LA reservoir function was described by using the LA total emptying volume = LAV_{max} − LAV_{min} and the LA total emptying fraction (LATF) = (LAV_{max} − LAV_{min})/LAV_{max}. The following parameters were measured to evaluate the LA conduit function: the LA passive emptying volume = LAV_{max} − LAV_{preA} and LA passive emptying fraction (LAEF) = (LAV_{max} − LAV_{preA})/LAV_{max}. Parameters of atrial booster pump function included: the LA active emptying volume = LAV_{preA} − LAV_{min} and the LA active emptying fraction (LAAF) = (LAV_{preA} − LAV_{min})/LAV_{preA} [27].

CMR atrial strain was analyzed and processed using commercial cardiovascular postprocessing software QStrain (version 3.1.16.9, MedisMedical Imaging Systems, Leiden, The Netherlands). Afterwards, according to the LA’s phasic functions, specific LA strains were then evaluated: LA-ε_{t} for the LA reservoir function, LA-ε_{p} for the LA passive emptying function, and LA-ε_{a} for the LA booster pump function [12].

2.4. Follow-Up of Clinical Outcomes

The clinical follow-up was obtained by completing questionnaires either during hospital visits, by telephone, or both, aiming at delineating the occurrence of the clinical outcomes, which corresponded to the first event occurring in each patient among the following MACEs: death, non-fatal cardiac arrest, ventricular tachyarrhythmia, and heart failure requiring hospitalization defined accordingly to current international guidelines. Survival analysis was performed for the clinical outcomes. The median follow-up was 26 months and maximum follow-up reached 41 months.

2.5. Statistical Analysis

All data were tested for normality using the Kolmogorov–Smirnov test. Continuous data were presented as median (inter-quartile range [IQR]) and mean ± standard deviation (SD). Discrete data were reported as percentages and frequencies. Baseline clinical and CRM data were analyzed according to LAε tertiles, using a trend test for categorical variables and 1-way ANOVA with Bonferroni correction or its nonparametric equivalents (Kruskal–Wallis test) for continuous variables. The correlations between the LAV index, parameters LA function and diastolic function were measured using the Pearson’s or Spearman correlation test, and the predictors for the LAV index were assayed using a linear regression model. Hazard ratios (HR) for the prediction of events were calculated using Cox regression models. For each outcome, we considered all the significant variables in the univariate analysis and sought the best overall multivariate models for the composite endpoint, by stepwise-forward selection, with a probability to enter set at p < 0.05 and to remove the effect of regression at p < 0.05. Time to event outcomes were analyzed using the Kaplan–Meier method and compared using the log-rank test. Multivariate analysis was
performed using a multiple logistical regression model for generation of hazard ratios (95% confidence interval). Cohen’s Kappa inter- and intra-observer coefficients were determined. Retrospective test power calculation and prospective sample size were estimated, with type I and type II variation according to sample size. Statistical significance was set as \( p \)-value < 0.05. Statistical analysis was performed using MedCalc (Version 19.1.7, MedCalc Software, Belgium).

3. Results

3.1. Baseline Characteristics

Overall, 212 patients with NIDCM (49 ± 14.2-year-old; 73.5% males) (Figure 1) and 106 healthy subjects who served as controls (49 ± 11.2-year-old; 70.7% males) were finally included in the study (Table 1).

| Table 1. Baseline characteristics of patients in study. |
|--------------------------------------------------------|
| NIDCM All Patients                                      |
| \( n = 212 \)                                           |
| Healthy Volunteers                                      |
| \( n = 106 \)                                           |
| \( p \)-Value                                           |
| Clinical characteristics                                |
| - Age, mean (SD), years                                 |
|   49 (14.2)                                             |
|   49 (11.8)                                             |
|   NS                                                    |
| - Male gender, \( n (%) \)                              |
|   156 (73.5)                                            |
|   75 (70.2)                                             |
|   NS                                                    |
| - Body-mass index, kg/m\(^2\)                          |
|   27.4 (4.7)                                            |
|   27.8 (4.8)                                            |
|   NS                                                    |
| - Heart rate, mean (SD), bpm                            |
|   73 (12.8)                                             |
|   73 (15.8)                                             |
|   NS                                                    |
| - Systolic blood pressure, mean (SD), mmHg              |
|   134 (19.1)                                            |
|   122 (17.2)                                            |
|   NS                                                    |
| - Hypertension, \( n (%) \)                            |
|   51 (24.0)                                             |
|   20 (18.9)                                             |
|   <0.01                                                 |
| - Diabetes mellitus, \( n (%) \)                       |
|   40 (18.8)                                             |
|   15 (14.1)                                             |
|   <0.01                                                 |
| - Dyslipidemia, \( n (%) \)                            |
|   96 (45.2)                                             |
|   49 (46.2)                                             |
|   NS                                                    |
| - Smoking, \( n (%) \)                                 |
|   64 (30.2)                                             |
|   37 (34.9)                                             |
|   NS                                                    |
| Biomarker levels                                        |
| - NT-proBNP, median (IQR), pg/mL                        |
|   2679 (378–11,960)                                     |
|   223 (60–391)                                          |
|   <0.001                                                |
| - eGFR, mean (SD), mL/min/1.73 m\(^2\)                 |
|   86.4 (20.1)                                           |
|   87.4 (16.8)                                           |
|   NS                                                    |
| - PICP, median (IQR), ng/mL                            |
|   1.45 (0.42–9.2)                                       |
|   0.47 (0.31–5.1)                                       |
|   <0.001                                                |
| - PIIINP, median (IQR), ng/mL                           |
|   15.6 (2.7–79.1)                                       |
|   8.2 (2.1–23.5)                                        |
|   <0.001                                                |
| - Galectin-3, median (IQR), ng/mL                       |
|   13.9 (2.2–21.6)                                       |
|   4.8 (1.2–12.8)                                        |
|   <0.001                                                |

Abbreviations: \( n \), number of patients; SD, standard deviation; IQR, interquartile range; NS, not significant; NIDCM, non-ischemic dilated cardiomyopathy; NT-proBNP, N-terminal pro-Brain Natriuretic Peptide; eGFR, estimated glomerular filtration rate; PICP, procollagen type I C-terminal propeptide; PIIINP, procollagen type III N-terminal propeptide; Data are reported as mean (standard deviation) or median (IQR) or \( n \) (%).

There were no significant differences between the two groups in terms of clinical characteristics. However, biomarkers of cardiac dysfunction and fibrosis were considerably higher in the diseased group \( (p < 0.001) \). Regarding the reproducibility of CMR parameters, measurements were repeatedly performed on the same set of images. For LAV\(_{\text{max}}\), LAV\(_{\text{min}}\), LAV\(_{\text{preA}}\), LASI and E/E’ ratio, the intra- and inter-observer reproducibility was very good, with kappa coefficients of inter-observer agreement 0.90 for LAV\(_{\text{max}}\), 0.93 for LAV\(_{\text{min}}\), 0.87 for LAV\(_{\text{preA}}\), 0.94 for LASI and 0.92 for E/E’ ratio, while the intra-observer coefficients were 0.93 for LAV\(_{\text{max}}\), 0.95 for LAV\(_{\text{min}}\), 0.91 for LAV\(_{\text{preA}}\), 0.94 for LASI and 0.96 for E/E’ ratio.

3.2. Characterization of LV Systolic and Diastolic Functions

CMR measurements showed an impaired LV systolic function in those with NIDCM (Table 2), characterized by substantially increased LVEDV, LVESV and LVM, and decreased LVEF \( (p < 0.001) \). LAS and LWSI were also defective in the NIDCM group \( (p < 0.001) \). LV diastolic function and transmitral parameters were notably impaired in the NIDCM group, namely E, DT, E/E’ ratio (all \( p < 0.001) \). Moreover, CMR flow parameters of EQ \( (p < 0.001) \), AQ \( (p < 0.001) \), QE/QA ratio \( (p < 0.05) \), and EQ/LVEDV \( (p < 0.001) \) were also significantly impaired in the NIDCM group.
### Table 2. Cardiac magnetic resonance imaging indices of systolic and diastolic function.

| Variables                                      | NIDCM All Patients | Healthy Volunteers | p-Value |
|------------------------------------------------|--------------------|--------------------|---------|
| **LV and RV systolic parameters**              |                    |                    |         |
| - LVEDV index, mL/m²                           | 131.5 (36.5)       | 63.1 (18.6)        | <0.001  |
| - LVESV index, mL/m²                           | 87.1 (36.2)        | 21.6 (7.4)         | <0.001  |
| - LVM index, g/m²                              | 86.1 (20.1)        | 58.4 (14.1)        | <0.001  |
| - LVEF, %                                      | 35.5 (10.1)        | 65.7 (5.6)         | <0.001  |
| - LAS, %                                       | −9.5 (5.4)         | −20.0 (2.7)        | <0.001  |
| - LVSI                                         | 0.40 (0.12)        | 0.18 (0.05)        | <0.001  |
| - LV-LGE mass, g                               | 34.4 (13.1)        | -                  | NA      |
| - LV-LGE mass/LVM, %                           | 18.1 (7.7)         | -                  | NA      |
| - RVESV index, mL/m²                           | 57.1 (24.0)        | 59.0 (19.3)        | NS      |
| - RVEDV index, mL/m²                           | 31.2 (17.6)        | 22.5 (8.1)         | <0.001  |
| - RVEF, %                                      | 46.8 (9.5)         | 61.8 (5.7)         | <0.001  |
| - TAPSE, mm                                     | 16.6 (5.1)         | 21.2 (2.9)         | <0.001  |
| **LV diastolic parameters**                    |                    |                    |         |
| - E, cm/s                                      | 52.1 (12.2)        | 75.5 (9.3)         | <0.001  |
| - A, cm/s                                      | 34.5 (9.4)         | 47.2 (6.9)         | NS      |
| - DT, ms                                       | 210 (80.3)         | 182 (58.5)         | <0.001  |
| - IVRT, ms                                     | 60 (18.7)          | 88 (18.1)          | NS      |
| - E', cm/s                                     | 6.2 (2.3)          | 5.8 (2.2)          | <0.01    |
| - A', cm/s                                     | 4.7 (1.2)          | 3.4 (1.3)          | NS      |
| - E/A ratio                                     | 1.46 (0.93)        | 1.85 (0.73)        | <0.05    |
| - E/E' ratio                                    | 9.5 (2.8)          | 6.5 (1.5)          | <0.001  |
| - EQ, mL/s                                     | 243 (112.8)        | 344 (90.7)         | <0.001  |
| - AQ, mL/s                                     | 213 (122.5)        | 205 (75.2)         | NS      |
| - EQ/LVEDV, s⁻¹                                 | 1.99 (0.61)        | 3.83 (1.42)        | <0.001  |
| - EQ / FV, s⁻¹                                  | 4.01 (1.2)         | 4.9 (0.82)         | NS      |
| - FV, mL                                       | 61.9 (21.4)        | 71.7 (20.1)        | NS      |

**Abbreviations:** n, number of patients; SD, standard deviation; IQR, interquartile range; NA, not applicable; NS, not significant; NIDCM, non-ischemic dilated cardiomyopathy; FV, mitral filling volume; LAS, left ventricular longitudinal-axis strain; LV-LGE, left ventricular late gadolinium enhancement; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; LVEF, left ventricular ejection fraction; LVSI, left ventricular sphericity index; A, late peak mitral flow velocity; A', myocardial longitudinal late diastolic peak myocardial velocity; E, early peak mitral flow velocity; E', myocardial longitudinal early diastolic peak myocardial velocity; AQ, late peak mitral flow-rate; EQ, early peak mitral flow-rate; DT, early diastolic filling deceleration time; IVRT, isovolumic relaxation time, TAPSE, tricuspid annular plane systolic excursion; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVEF, right ventricular ejection fraction. Data are reported as mean (standard deviation) or median (IQR) or n (%).

### 3.3. Characterization of LA Phasic Function and Geometry

CMR measurements of LA phasic function and geometry are presented in Table 3. LA volumes were significantly increased in NIDCM group (all p < 0.001). All three LA phasic functions and strain patterns were significantly impaired in the NIDCM group, namely for LA reservoir function: LATF (43.7% ± 8.5 vs. 58.9% ± 2.9 (p < 0.001) and LA-εₜ (31.5% ± 2.4 vs. 39.8% ± 2.8, p < 0.001), for LA conduit function: LAPF (20.9% ± 7.2 vs. 29.1% ± 8.4, p < 0.001), LA-εₚ (16.0% ± 4.1 vs. 17.9% ± 2.7, p < 0.001) and for LA atrial booster function: LAAF (28.6% ± 9.6 vs. 41.3% ± 8.3, p < 0.001), LA-ε₃ (20.6% ± 2.5 vs. 29.2% ± 3.6, p < 0.001).

LASI was significantly increased in the NIDCM group compared to the healthy volunteers group (0.77 vs. 0.39, p < 0.001), while 57% of patients were positive for atrial replacement fibrosis represented by LA-LGE.
### Table 3. Comparison between left atrial function and geometry parameters between NIDCM and healthy volunteers.

| Variables                      | NIDCM All Patients | Healthy Volunteers | p-Value |
|--------------------------------|--------------------|--------------------|---------|
| LA volumes indexed             |                    |                    |         |
| - LAV<sub>max</sub> index, mL/m<sup>2</sup> | 56.1 (21.7)         | 34.0 (6.2)         | <0.001  |
| - LAV<sub>min</sub> index, mL/m<sup>2</sup> | 32.4 (9.5)          | 14.0 (2.7)         | <0.001  |
| - LAV<sub>pre-A</sub> index, mL/m<sup>2</sup> | 45.3 (11.1)         | 24.1 (4.7)         | <0.001  |
| Reservoir function             |                    |                    |         |
| - LATF, %                      | 43.7 (8.5)          | 58.9 (2.9)         | <0.001  |
| - LA-ε<sub>t</sub>, (%)        | 31.5 (2.4)          | 39.8 (2.8)         | <0.001  |
| Conduit function               |                    |                    |         |
| - LAPF, %                      | 20.9 (7.2)          | 29.1 (8.4)         | <0.001  |
| - LA-ε<sub>p</sub>, (%)        | 16.0 (4.1)          | 17.9 (2.7)         | <0.001  |
| Atrial booster function        |                    |                    |         |
| - LAAF, %                      | 28.6 (9.6)          | 41.3 (8.3)         | <0.001  |
| - LA-ε<sub>a</sub>, (%)        | 20.6 (2.5)          | 29.2 (3.6)         | <0.001  |
| LA geometry                    |                    |                    |         |
| - LASI                          | 0.77 (0.23)         | 0.39 (0.06)        | <0.001  |
| - LA-LGE +, n (%)               | 121 (57)            | -                  | NA      |
| Severe mitral regurgitation, n (%) | 60 (28.3)          | -                  | NA      |

Abbreviations: LA-ε<sub>a</sub>, left atrial active strain; LA-ε<sub>p</sub>, left atrial passive strain; LA-ε<sub>t</sub>, left atrial total strain; LAAF, left atrial active emptying function; LAPF, left atrial passive emptying function; LASI, left atrial sphericity index; LATF, left atrial total emptying function; LAV<sub>max</sub>, maximum left atrial volume; LAV<sub>min</sub>, minimum left atrial volume; LAV<sub>pre-A</sub>, pre-atrial contraction left atrial volume; LA-LGE, left atrial late gadolinium enhancement; NA, not applicable; NIDCM, non-ischemic dilated cardiomyopathy.

### 3.4. Correlations between LA Function, Geometry, and LV Function Parameters in Patients with NIDCM

The most relevant correlations between LA function, geometry and LV function are presented in Table 4. LA phasic function and strain parameters were inversely associated with LA geometry. Amongst them, LAV<sub>min</sub> proved to have the most powerful correlations with LATF, LAPF, LAAF, LA-ε<sub>t</sub> and LA-ε<sub>a</sub> (p < 0.0001), while LAV<sub>pre-A</sub> and LASI were correlated with LAPF and LA-ε<sub>t</sub> (p < 0.0001).

Regarding LA function and LV conventional function parameters, apart from LVEF which was positively associated with all LA functional parameters, other LV function measurements were negatively correlated with the LA ones. LVEF had the strongest associations with LATF, LAAF, LA-ε<sub>t</sub> and LA-ε<sub>a</sub> (p < 0.0001). LVEDV and LVESV were negatively correlated with LATF, LAAF, LA-ε<sub>t</sub> and LA-ε<sub>a</sub> (p < 0.0001). LAS was also inversely associated with LATF, LAAF, LA-ε<sub>t</sub> and LA-ε<sub>a</sub> (p < 0.0001).

### Table 4. Correlations between LA function and parameters of LA geometry and LV function in the NIDCM group.

|                   | LATF   | LAPF   | LAAF   | LA-ε<sub>t</sub> | LA-ε<sub>p</sub> | LA-ε<sub>a</sub> |
|-------------------|--------|--------|--------|------------------|------------------|------------------|
| **LA geometry**   |        |        |        |                  |                  |                  |
| LAV<sub>max</sub> index, mL/m<sup>2</sup> | -0.489 (0.0001) | -0.201 (0.003) | -0.464 (0.0001) | -0.459 (0.0001) | -0.222 (0.001) | -0.394 (0.0001) |
| LAV<sub>min</sub> index, mL/m<sup>2</sup> | -0.817 (0.0001) | -0.419 (0.0001) | -0.713 (0.0001) | -0.663 (0.0001) | -0.273 (0.001) | -0.597 (0.0001) |
| LAV<sub>pre-A</sub> index, mL/m<sup>2</sup> | -0.682 (0.0001) | -0.519 (0.0001) | -0.484 (0.0001) | -0.641 (0.0001) | -0.208 (0.002) | -0.602 (0.0001) |
| LASI              | -0.587 (0.0001) | -0.263 (0.001) | -0.546 (0.0001) | -0.635 (0.0001) | -0.277 (0.001) | -0.565 (0.0001) |
Table 4. Cont.

| LA Phasic Function Parameters | LATF | LAFP | LAAF | LA-ε_t | LA-ε_p | LA-ε_a |
|-------------------------------|------|------|------|--------|--------|--------|
| **LV conventional function**  |      |      |      |        |        |        |
| LVEDV index, mL/m²            | −0.583 (0.001) | −0.336 (<0.0001) | −0.500 (<0.0001) | −0.655 (<0.0001) | −0.199 (0.004) | −0.627 (<0.0001) |
| LVEF, %                       | 0.673 (<0.0001) | 0.386 (<0.0001) | 0.576 (<0.0001) | 0.765 (<0.0001) | 0.223 (0.001) | 0.736 (<0.0001) |
| LVSI                          | −0.150 (0.02) | −0.170 (0.01) | −0.058 (0.39) | −0.156 (0.02) | −0.073 (0.28) | −0.114 (0.09) |
| LAS, %                        | −0.618 (<0.0001) | −0.336 (<0.0001) | −0.537 (<0.0001) | −0.628 (0.018) | −0.175 (0.001) | −0.619 (<0.0001) |
| E/E’ ratio                    | −0.400 (<0.0001) | −0.260 (<0.0001) | −0.313 (<0.0001) | −0.387 (<0.0001) | −0.063 (0.26) | −0.399 (<0.0001) |

Abbreviations: NIDCM, non-ischemic dilated cardiomyopathy; LA-ε_a, left atrial active strain; LA-ε_p, left atrial passive strain; LA-ε_t, left atrial total strain; LA, left atrium; LAAF, left atrial active emptying function; LAFE, left atrial passive emptying function; LAS, left ventricular long-axis strain; LASI, left atrial sphericity index; LATF, left atrial total emptying function; LAV_max, maximum left atrial volume; LAV_min, minimum left atrial volume; LAV_pre-A, pre-atrial contraction left atrial volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LA-LGE, left atrial late gadolinium enhancement; LASI, left atrial sphericity index; LATF, left atrial total emptying fraction; LA-ε_t, left atrial total strain; LVSI, left ventricular sphericity index; LVEDV, left ventricular end-diastolic volume. Table data are the coefficients of correlations.

3.5. Univariate and Multivariate Analysis of LA Function and Geometry Parameters

Patients with NIDCM were followed-up for a median of 26 months. Of all, 7 experienced cardiac death, 14 ventricular tachyarrhythmias, and 19 heart failure hospitalization. Cox regression analyses were performed to evaluate the ability of LA parameters to predict the composite outcome (Table 5).

Table 5. Univariable and Multivariable Cox Regression Analyses: Association of left atrial functional indices with the composite end point.

| Univariate HR (95% CI) | Multivariate |
|------------------------|--------------|
|                        | Model 1      | Model 2      | Model 3      | Model 4      |
| **LAV_max index**      | 1.02 (1.01–1.03) | 1.01 (1.00–1.02) | 1.02 (1.00–1.03) | 1.01 (1.01–1.03) | 1.02 (1.00–1.05) | p < 0.01 |
| **LAV_min index**      | 1.03 (1.00–1.04) | 1.04 (1.01–1.07) | 1.05 (1.02–1.08) | 1.03 (1.00–1.07) | 1.04 (1.02–1.07) | p < 0.01 |
| **LAV_pre-A index**    | 1.03 (1.01–1.05) | 1.06 (1.01–1.06) | 1.07 (1.02–1.12) | 1.05 (1.01–1.07) | 1.06 (1.04–1.11) | p < 0.01 |
| **LASI**               | 2.07 (1.37–4.52) | 1.83 (1.22–4.10) | 1.74 (1.02–3.77) | 1.76 (1.14–3.18) | 1.16 (1.03–1.32) | p < 0.01 |
| **LA-LGE**             | 3.83 (1.90–7.71) | 4.12 (2.03–8.31) | 4.03 (1.95–8.31) | 4.04 (1.95–8.33) | 4.52 (2.03–10.06) | p < 0.001 |
| **LA-ε_t**             | 4.14 (2.09–8.18) | 4.46 (2.23–8.91) | 4.38 (2.18–8.77) | 4.61 (2.27–9.36) | 3.81 (1.78–8.12) | p = 0.001 |

Abbreviations: EQ, trans-mitral early peak flow-rate; LAV_max, maximum left atrial volume; LAV_min, minimum left atrial volume; LAV_pre-A, pre-atrial contraction left atrial volume; LA-LGE, left atrial late gadolinium enhancement; LASI, left atrial sphericity index; LATF, left atrial total emptying fraction; LA-ε_t, left atrial total strain; LVSI, left ventricular sphericity index; LVEDV, left ventricular end-diastolic volume. Adjustment models: age, gender with the addition of significant parameters of univariable analysis. Data are hazard ratio (95% CI). Model 1 = adjusted for age + gender; Model 2 = Model 1 + mitral regurgitation severity Model 3 = Model 2 + LATF Model 4 = Model 3 + LAS + LVEF.
In unadjusted analysis, LA volumes, LASI, LA-LGE and LA-εt were significantly correlated with increased risk for the outcome and persisted even after adjustments for specific clinical and CMR covariates. Furthermore, in unadjusted analysis, LASI had an HR for the composite outcome of 2.07 \( (p < 0.001) \). This decreased to 1.16 \( (p < 0.001) \) in multivariate analysis. LA-εt was associated with the increased composite outcome (HR 4.14, \( p < 0.0001 \)). The HR decreased slightly to 3.81 when covariates were added to the analysis. The prediction ability of LA-LGE increased after the adjustment of covariates from HR of 3.83 \( (p < 0.001) \) to 4.52 \( (p = 0.0001) \).

### 3.6. Time to Event Analysis and Incremental Predictive Ability of LA Function and Geometry Parameters

Kaplan–Meier analysis was used to test the ability of LA volumes, LASI and LA-εt for predicting the composite outcome. Hence, for LA geometry, Kaplan–Meier analysis demonstrated higher risk for composite outcomes with higher LA volumes (LAV\(_\text{max}\) > 54 mL/m\(^2\) \( [\text{HR} = 2.02; 95\%\text{CI} (1.07–3.83), p < 0.03] \)), LAV\(_\text{min}\) > 31 mL/m\(^2\) \( [\text{HR} = 1.66; 95\%\text{CI} (1.08–3.15), p < 0.01] \), LAV\(_\text{pre-A}\) > 43 mL/m\(^2\) \( [\text{HR} = 2.11; 95\%\text{CI} (1.11–3.99), p < 0.02] \)), and with LASI > 0.725, \( (\text{HR} = 2.68; 95\%\text{CI} (1.42–5.07), p < 0.003) \) (Figure 2).

**Figure 2.** Kaplan–Meier curves for time to event analysis of: LAV\(_\text{max}\) (A), LAV\(_\text{min}\) (B), LAV\(_\text{pre-A}\) (C) and LASI (D). Abbreviations: LAV\(_\text{max}\), maximum left atrial volume; LAV\(_\text{min}\), minimum left atrial volume; LAV\(_\text{pre-A}\), pre-atrial contraction left atrial volume; LASI, left atrial sphericity index.
Patients were divided in three subgroups based on the LA function and according to LA-$\varepsilon_t$ tertiles, to evaluate if the severity of LA phasic dysfunction impacts the prediction of the composite outcome. Hence, 42 patients had mild impairment of LA-$\varepsilon_t > 35\%$ (tertile 1), 58 patients had moderate impairment of LA-$\varepsilon_t 30-35\%$ (tertile 2) and 112 patients had severe impairment of the LA-$\varepsilon_t < 30\%$ (tertile 3). Kaplan–Meier analysis demonstrated that patients with LA-$\varepsilon_t < 30\%$ had a higher risk for the composite outcome. Additionally, during the follow-up period, the composite outcome occurred in 25.9% of patients with LA-$\varepsilon_t < 30\%$ (tertile 3), while occurrence in the other two categories was lower (Figure 3).

![Kaplan–Meier curves for time to event analysis of LA-$\varepsilon_t$. Abbreviations: LA-$\varepsilon_t$, left atrial total strain.](image)

Stepwise Cox proportional-hazards models showed that these parameters had considerable predictive value for the composite outcome (Figure 4). Foremost, the addition of LASI to LA-$\varepsilon_t$ significantly increased the predictive ability (Chi-square = 10.2, $p < 0.001$), while the further addition of LA-LGE to them enhanced it even more (Chi-Square = 15.8; $p < 0.0001$).
4. Discussion

In this prospective study, it was shown that a comprehensive appraisal of LA function and geometry using CMR provides valuable information in patients with NIDCM. The major findings of the current research comprise (1) LA function and geometry parameters were significantly impaired in those with NIDCM, when compared to the control group; (2) afflicted LA function and strain parameters were correlated with impaired LA geometry and LV dysfunction; (3) LA-εt, LASI and LA-LGE were considerably better at predicting composite outcome than other LA measurements, being also independently correlated with it; (4) the severity of LA-εt was significantly associated with the outcome; (5) LA-εt, LASI and LA-LGE added incremental predictive value for the outcome, beyond other parameters. Furthermore, this is the first study to assess the predictive ability of LA-εt by CMR in patients with NIDCM.

As a direct result of impaired LV, LA enlargement and dysfunction with defective LA phasic functions are frequent in cardiac conditions [5,11,28–30]. First and foremost, studies that analyzed the role of echocardiography in LA remodelling, phasic function and geometry have begun to emerge. They had shown that LA phasic function parameters were strongly associated with HF, impaired LV relaxation and compliance, atrial fibrillation and AHT [10,20,31–33]. LA conduit function was found to be defective even before LV hypertrophy and enlargement occurred [34], and to be directly associated with diastolic dysfunction, its severity [32] and progression [35]. Moreover, LA reservoir function was notably linked to cardiac dysfunction in diabetic [36] and cancer patients [37]. Additionally,
the role of LA strain had been certified, being considerably linked to disease severity, HF hospitalization and mortality [38].

The role of CMR in evaluating these parameters has recently been endorsed by certain studies, but more work is required [11,27,31]. In the current study, all CMR measurements of LA dysfunction and altered geometry were notably flawed. Due to the lack of specific thresholds, these findings required validation by comparison with healthy individuals which served as a control group. Hence, CMR proved tremendous ability in characterizing LA malfunction and remodelling. Moreover, LA volumes were significantly increased in the diseased group, akin to other published data [2,3,14,15,32]. All LA phasic functions were considerably defective when compared with the control group, while corresponding LA strains were significantly impaired in patients with NIDCM, analogously to other published research [12]. Withal, in the diseased group, LASI was found to be considerably increased, whereas over half of patients had LA irreversible replacement fibrosis measured by LA-LGE, both being recently recognized as markers of LA remodelling [39–41].

Thereafter, the appositeness of LA function and geometry parameters was subsequently tested. The LA phasic function parameters were inversely related to LA volumes and geometry measurements, thus suggesting that LA dilation and remodelling are closely linked to defective LA function. Notwithstanding, \( \text{LAV}_{\text{min}}, \text{LAV}_{\text{pre-A}} \) and LASI correlated the best both reservoirs (LATF and LA-\( \varepsilon_t \)) and atrial booster functions (LAAF and LA-\( \varepsilon_a \)). The relevancy of LA volumes and LASI had been endorsed by recently published data, especially regarding \( \text{LAV}_{\text{min}} \) and LASI [19,42]. LVEDV and LVESV were inversely associated with LA phasic functions, remarkably with LA reservoir and atrial booster functions. Furthermore, LVEF was positively linked to these functional measurements, albeit its progressive worsening was closely related to LA dysfunction. These findings are comparable to other published studies, which had also found substantial associations between impaired LA phasic functions and LV dysfunction [11,24,25,30].

Furthermore, relevant LA parameters were selected using the regression coefficients and comprised LA volumes, LA-\( \varepsilon_t \), LASI and LA-LGE, all providing significant predictive ability. LA volumes were independently associated with composite outcome, while Kaplan–Meier analysis showed significant predictive ability. Similarly, other published studies endorsed the importance of CMR-determined LA volumes as independent outcome predictors [42–44]. However, in contrast with other reported data, this is the first study to suggest that LA volume parameters were outranked by LA geometry and fibrosis measurements. These findings put forward that LA dysfunction has other determinants, besides LA dilation. Moreover, LASI proved an outstanding prognostic ability for the composite outcomes, even after the adjustment for covariates (model 4). Additionally, Kaplan–Meier analysis confirmed the predictive capacity of LASI > 0.725. This marker has been recently described as an indicator of LA remodelling, in both CMR and echocardiography studies, being able to predict atrial fibrillation’s recurrence and HF hospitalization [19,34,39]. To our knowledge, this is the first study to evaluate the ability of LASI to predict cardiovascular mortality.

Moreover, our study is the first to evaluate the prognostic role of LA-\( \varepsilon_t \) in patients with NIDCM. At first, the prognostication capacity of LA-\( \varepsilon_t \) was tested and showed a remarkable predictive ability for outcome. Thereafter, to evaluate the relationship between the severity of LA-\( \varepsilon_t \) and composite outcome, specific LA-\( \varepsilon_t \) tertiles were created and patients were segregated accordingly. Time to event analysis showed significant predictive ability, especially for those with severe impairment of LA-\( \varepsilon_t \) (third tertile; LA-\( \varepsilon_t < 30\% \)). The predictive role of LA strain had been previously shown in both echocardiography and CMR studies, in other cardiovascular diseases [12,31,38,40]. To date, this is the first study to prove the predictive ability of LA-\( \varepsilon_t \) in NIDCM.

Lastly, using Cox regression models, the incremental predictive value of these parameters was evaluated. Hence, the embedment of LASI to LA-\( \varepsilon_t \) provided a significant incremental value, while the addition of LA-LGE improved even more the prediction of
composite outcome. To our knowledge, this is the first study to evaluate the incremental predictive value of combined LA function, geometry and fibrosis parameters using CMR.

As for the study’s limitations, firstly, this is a single-center study. Secondly, phase-contrast volume CMR is still a novel method to assess the LA and several technical errors might have occurred. Thirdly, specific thresholds for LA-εt are lacking and reference intervals still require large cohort populational studies. Finally, patients did not benefit from cardiac resynchronization therapy with a defibrillator which might have positively influenced their prognosis.

5. Conclusions

In patients with NIDCM, LA function and geometry are substantially impaired and considerably associated with LV dysfunction. Parameters of LA function (LA-εt), geometry (LASI) and myocardial fibrosis (LA-LGE) are independent predictors for HF hospitalization all-cause mortality. Furthermore, they provide incremental prognostication value beyond age, gender, LV conventional systolic and diastolic parameters, and LV geometry and strain.

Author Contributions: B.O.C.-M. and L.A.-C., conception and design of the study; L.A.-C. acquisition, analysis, and interpretation of data; statistical methods and interpretation of results; project administration. A.Z., I.D.M., C.C., D.H., R.-I.O., L.D., A.C.V. and M.F., acquisition, analysis, and interpretation of data; critical revision of the manuscript for intellectual content. B.O.C.-M., A.Z. and L.A.-C., drafting of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The current study did not receive any external funding.

Institutional Review Board Statement: The current study was approved by the Ethics Committee of the Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca (decision number 280 from 26th July 2017). The research was conducted in accordance with the Declaration of Helsinki.

Informed Consent Statement: All subjects who were enrolled in the study gave signed informed consent.

Acknowledgments: This work was supported by an internal institutional doctoral fellowship from the Iuliu Hatieganu University of Medicine and Pharmacy of Cluj-Napoca.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Pinto, Y.M.; Elliott, P.M.; Arbustini, E.; Adler, Y.; Anastasakis, A.; Böhm, M.; Duboc, D.; Gimeno, J.; de Groote, P.; Imazio, M.; et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 2016, 37, 1850–1858. [CrossRef]

2. Modena, M.G.; Muia, N.; Sgura, F.A.; Molinari, R.; Castelli, A.; Rossi, R. Left atrial size is the major predictor of cardiac death and overall clinical outcome in patients with dilated cardiomyopathy: A long-term follow-up study. Clin. Cardiol. 1997, 20, 553–560. [CrossRef]

3. Dini, F.L.; Cortigiani, L.; Baldini, U.; Boni, A.; Nuti, R.; Barsotti, L.; Micheli, G. Prognostic value of left atrial enlargement in patients with idiopathic dilated cardiomyopathy and ischemic cardiomyopathy. Am. J. Cardiol. 2002, 89, 518–523. [CrossRef]

4. Kuchynka, P.; Podzimkova, J.; Masek, M.; Lambert, L.; Cerny, V.; Danek, B.; Palecek, T. The Role of Magnetic Resonance Imaging and Cardiac Computed Tomography in the Assessment of Left Atrial Anatomy, Size, and Function. Biomed Res. Int. 2015, 2015, 1–13. [CrossRef]

5. Blume, G.G.; Mcleod, C.J.; Barnes, M.E.; Seward, J.B.; Pellikka, P.A.; Bastiansen, P.M.; Tsang, T.S.M. Left atrial function: Physiology, assessment, and clinical implications. Eur. J. Echocardiogr. 2011, 12, 421–430. [CrossRef] [PubMed]

6. Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afifalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Hear. J.-Cardiovasc. Imaging 2015, 16, 233–271. [CrossRef]

7. Matsuda, Y.; Toma, Y.; Ogawa, H.; Matsuzaki, M.; Katayama, K.; Fujii, T.; Yoshino, F.; Moritani, K.; Kumada, T.; Kusukawa, R. Importance of left atrial function in patients with myocardial infarction. Circulation 1983, 67, 566–571. [CrossRef]
8. Gan, G.C.H.; Ferkh, A.; Boyd, A.; Thomas, L. Left atrial function: Evaluation by strain analysis. *Cardiovasc. Diagn. Ther.* 2018, 8, 29–46. [CrossRef]

9. Truong, V.T.; Palmer, C.; Wolking, S.; Sheets, B.; Young, M.; Ngo, T.N.M.; Taylor, M.; Nagueh, S.F.; Zareba, K.M.; Raman, S.; et al. Normal left atrial strain and strain rate using cardiac magnetic resonance feature tracking in healthy volunteers. *Eur. Heart J.–Cardiovasc. Imaging* 2019. [CrossRef] [PubMed]

10. Rosca, M.; Lancellotti, P.; Popescu, B.A.; Pierard, L.A. Left atrial function: Pathophysiology, echocardiographic assessment, and clinical applications. *Heart* 2011, 97, 1982–1989. [CrossRef]

11. Chirinos, J.A.; Sardana, M.; Ansari, B.; Satija, V.; Kuriakose, D.; Edelstein, I.; Oldland, G.; Miller, R.; Gaddam, S.; Lee, J.; et al. Left Atrial Phasic Function by Cardiac Magnetic Resonance Feature Tracking Is a Strong Predictor of Incident Cardiovascular Events. *Circ. Cardiovasc. Imaging* 2018, 11. [CrossRef]

12. Kowallick, J.T.; Kutty, S.; Edelmann, F.; Chiribiri, A.; Villa, A.; Steinmetz, M.; Sohns, J.M.; Staab, W.; Bettencourt, N.; Unterberg-Buchwald, C.; et al. Quantification of left atrial strain and strain rate using Cardiovascular Magnetic Resonance myocardial feature tracking: A feasibility study. *J. Cardiovasc. Magn. Reson.* 2014, 16, 60. [CrossRef]

13. Thomas, L.; Marwick, T.H.; Popescu, B.A.; Donal, E.; Badano, L.P. Left Atrial Structure and Function, and Left Ventricular Diastolic Dysfunction. *J. Am. Coll. Cardiol.* 2019, 73, 1961–1977. [CrossRef] [PubMed]

14. Hoit, B.D. Left Atrial Size and Function. *J. Am. Coll. Cardiol.* 2014, 63, 493–505. [CrossRef]

15. Nagueh, S.F.; Smiseth, O.A.; Appleton, C.P.; Byrd, B.F.; Dokainish, H.; Edvardsen, T.; Flachskampf, F.A.; Gillebert, T.C.; Klein, A.L.; Lancellotti, P.; et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur. Heart J.–Cardiovasc. Imaging* 2016, 17, 1321–1360. [CrossRef]

16. Patel, D.A.; Lavie, C.J.; Gilliland, Y.E.; Shah, S.B.; Dinshaw, H.K.; Milani, R.V. Prediction of All-Cause Mortality by the Left Atrial Volume Index in Patients With Normal Left Ventricular Filling Pressure and Preserved Ejection Fraction. *Mayo Clin. Proc.* 2015, 90, 1499–1505. [CrossRef]

17. Khan, M.A.; Yang, E.Y.; Zhan, Y.; Judd, R.M.; Chan, W.; Nabi, F.; Heitner, J.F.; Kim, R.J.; Klem, I.; Nagueh, S.F.; et al. Association of left atrial volume index and all-cause mortality in patients referred for routine cardiovascular magnetic resonance: A multicenter study. *J. Cardiovasc. Magn. Reson.* 2019, 21, 4. [CrossRef]

18. Bisbal, F.; Guix, E.; Calvo, N.; Marin, D.; Berruezo, A.; Arbelo, E.; Ortiz-Pérez, J.; de Caralt, T.M.; Tolosana, J.M.; Borràs, R.; et al. Left Atrial Sphericity: A New Method to Assess Atrial Remodeling. Impact on the Outcome of Atrial Fibrillation Ablation. *J. Cardiovasc. Electrophysiol.* 2013, 24, 752–759. [CrossRef]

19. Nakamori, S.; Ngo, L.H.; Tugal, D.; Manning, W.J.; Nezafat, R. Incremental Value of Left Atrial Geometric Remodeling in Predicting Late Atrial Fibrillation Recurrence After Pulmonary Vein Isolation: A Cardiovascular Magnetic Resonance Study. *J. Am. Heart Assoc.* 2018, 7. [CrossRef]

20. Yazaki, M.; Nabeta, T.; Inomata, T.; Maemura, K.; Oki, T.; Fujita, T.; Ikeda, Y.; Ishii, S.; Naruke, T.; Inoue, Y.; et al. Clinical significance of left atrial geometry in dilated cardiomyopathy patients: A cardiovascular magnetic resonance study. *Clin. Cardiol.* 2021, 44, 222–229. [CrossRef]

21. Kramer, C.M.; Barkhausen, J.; Flamm, S.D.; Kim, R.J.; Nagel, E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. *J. Cardiovasc. Magn. Reson.* 2013, 15, 91. [CrossRef]

22. Bollache, E.; Redheuil, A.; Clément-Guinaudeau, S.; Defrance, C.; Perdrix, L.; Ladoucer, M.; Lefort, M.; De Cesare, A.; Herment, A.; Diebold, B.; et al. Automated left ventricular diastolic function evaluation from phase-contrast cardiovascular magnetic resonance and comparison with Doppler echocardiography. *J. Cardiovasc. Magn. Reson.* 2010, 12, 63. [CrossRef]

23. Liang, Y.; Li, W.; Zeng, R.; Sun, J.; Wan, K.; Xu, Y.; Cao, Y.; Zhang, Q.; Han, Y.; Chen, Y. Left Ventricular Spherical Index Is an Independent Predictor for Clinical Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. *JACC Cardiovasc. Imaging* 2019, 12, 1578–1580. [CrossRef]

24. Cerqueira, M.D.; Weissman, N.J.; Dilsizian, V.; Jacobs, A.K.; Kaul, S.; Laskey, W.K.; Pennell, D.J.; Rumberger, J.A.; Ryan, T.; Verani, M.S. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. *Circulation* 2002, 105, 539–542. [CrossRef] [PubMed]

25. Bondarenko, O.; Beek, A.; Hofman, M.; Kühll, H.; Twisk, J.; van Dockum, W.; Visser, C.; van Rossum, A. Standardizing the Definition of Hyperenhancement in the Quantitative Assessment of Infarct Size and Myocardial Viability Using Delayed Contrast-Enhanced CMR. *J. Cardiovasc. Magn. Reson.* 2005, 7, 481–485. [CrossRef]

26. Habibi, M.; Zareian, M.; Ambale Venkatesh, B.; Samiei, S.; Imai, M.; Wu, C.; Launer, L.J.; Shea, S.; Gottesman, R.F.; Heckbert, S.R.; et al. Left Atrial Mechanical Function and Incident Ischemic Cerebrovascular Events Independent of AF. *JACC Cardiovasc. Imaging* 2019, 12, 2417–2427. [CrossRef]

27. Reiber, J.H.C.; Alaiti, A.; Bezerra, H.G.; de Sutter, J.; Schoenhagen, P.; Stillman, A.E.; Van de Veire, N.R.L. Cardiovascular imaging 2017 in the International Journal of Cardiovascular Imaging. *Int. J. Cardiovasc. Imaging* 2018, 34, 833–848. [CrossRef]

28. Farhad, H.; Seidelmann, S.B.; Vigneault, D.; Abbasi, S.A.; Yang, E.; Day, S.M.; Colan, S.D.; Russell, M.W.; Towsb, J.; Sherrid, M.V.; et al. Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. *J. Cardiovasc. Magn. Reson.* 2017, 19, 107. [CrossRef]
29. Liu, S.; Ma, C.; Ren, W.; Zhang, J.; Li, N.; Yang, J.; Zhang, Y.; Qiao, W. Regional left atrial function differentiation in patients with constrictive pericarditis and restrictive cardiomyopathy: A study using speckle tracking echocardiography. *Int. J. Cardiovasc. Imaging* 2015, 31, 1529–1536. [CrossRef]

30. Welles, C.C.; Ku, I.A.; Kwan, D.M.; Whooley, M.A.; Schiller, N.B.; Turakhia, M.P. Left Atrial Function Predicts Heart Failure Hospitalization in Subjects With Preserved Ejection Fraction and Coronary Heart Disease. *J. Am. Coll. Cardiol.* 2012, 59, 673–680. [CrossRef]

31. Zhu, M.; Chen, H.; Liu, Y.; Shu, X. Clinical implication of disturbed left atrial phasic functions in the heterogeneous population associated with hypertension or atrial fibrillation. *Cardiovasc. Ultrasound* 2019, 17, 25. [CrossRef] [PubMed]

32. Yamano, M.; Yamano, T.; Iwamura, Y.; Nakamura, T.; Shiraishi, H.; Shirayama, T.; Matoba, S. Impact of Left Ventricular Diastolic Property on Left Atrial Function from Simultaneous Left Atrial and Ventricular Three-Dimensional Echocardiographic Volume Measurement. *Am. J. Cardiol.* 2017, 119, 1687–1693. [CrossRef] [PubMed]

33. Tsai, W.-C.; Huang, Y.-Y.; Liu, Y.-W.; Shih, J.-Y.; Lin, C.-C.; Tsai, L.-M. Changes of Left Atrial Phasic Function Assessed by Speckle Tracking Echocardiography in Untreated Hypertension. *J. Med. Ultrasound* 2012, 20, 220–227. [CrossRef]

34. Yang, Y.; Yin, G.; Jiang, Y.; Song, L.; Zhao, S.; Lu, M. Quantification of left atrial function in patients with non-obstructive hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking imaging: A feasibility and reproducibility study. *J. Cardiovasc. Magn. Reson.* 2020, 22, 1. [CrossRef]

35. Nappo, R.; Degiovanni, A.; Bolzani, V.; Sartori, C.; Di Giovine, G.; Cerini, P.; Fossaeco, R.; Kovács, S.J.; Marino, P.N. Quantitative assessment of atrial conduit function: A new index of diastolic dysfunction. *Clin. Res. Cardiol.* 2016, 105, 17–28. [CrossRef]

36. Tadic, M.; Vukomanovic, V.; Cuspidi, C.; Suzic-Lazic, J.; Stanisavljevic, D.; Celic, V. Left atrial phasic function and heart rate variability in asymptomatic diabetic patients. *Acta Diabetol.* 2017, 54, 301–308. [CrossRef] [PubMed]

37. Tadic, M.; Genger, M.; Cuspidi, C.; Belyavskiy, E.; Frydas, A.; Dordevic, A.; Morris, D.A.; Völkl, J.; Parwani, A.S.; Pieske, B.; et al. Phasic Left Atrial Function in Cancer Patients Before Initiation of Anti-Cancer Therapy. *J. Clin. Med.* 2019, 8, 421. [CrossRef]

38. Carluccio, E.; Biagioli, P.; Mengoni, A.; Francesca Cerasa, M.; Lauciello, R.; Zuchi, C.; Bardelli, G.; Alunni, G.; Coiro, S.; Gronda, E.G.; et al. Left Atrial Reservoir Function and Outcome in Heart Failure With Reduced Ejection Fraction. *Circ. Cardiovasc. Imaging* 2018, 11. [CrossRef]

39. Yazaki, M.; Nabeto, T.; Inomata, T.; Maemura, K.; Oki, T.; Fujita, T.; Ikeda, Y.; Ishii, S.; Naruke, T.; Ako, J. Clinical significance of left atrial geometry in patients with dilated cardiomyopathy: A cardiovascular magnetic resonance study. *Eur. Heart J.* 2020, 41. [CrossRef]

40. Shi, J.; Xu, S.; Chen, L.; Wu, B.; Yang, K.; Chen, S.; Zhou, D.; Zhang, B.; Xuan, T.; Hu, X. Impact of Left Atrial Sphericity Index on the Outcome of Catheter Ablation for Atrial Fibrillation. *J. Cardiovasc. Transl. Res.* 2021. [CrossRef] [PubMed]

41. Quail, M.; Grunseich, K.; Baldassarre, I.A.; Mojibian, H.; Marieb, M.A.; Corfeld, D.; Soufer, A.; Sinusas, A.J.; Peters, D.C. Prognostic and functional implications of left atrial late gadolinium enhancement cardiovascular magnetic resonance. *J. Cardiovasc. Magn. Reson.* 2019, 21, 2. [CrossRef]

42. Habibi, M.; Chahal, H.; Opdahl, A.; Gjesdal, O.; Helle-Valle, T.M.; Heckbert, S.R.; McClelland, R.; Wu, C.; Shea, S.; Hundley, G.; et al. Association of CMR-Measured LA Function With Heart Failure Development. *JACC Cardiovasc. Imaging* 2014, 7, 570–579. [CrossRef]

43. Gulati, A.; Ismail, T.F.; Jabbour, A.; Ismail, N.A.; Morarji, K.; Ali, A.; Raza, S.; Khwaja, J.; Brown, T.D.H.; Liodakis, E.; et al. Clinical utility and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non-ischaemic dilated cardiomyopathy. *Eur. J. Heart Fail.* 2013, 15, 660–670. [CrossRef] [PubMed]

44. Habibi, M.; Samiei, S.; Ambale Venkatesh, B.; Opdahl, A.; Helle-Valle, T.M.; Zareian, M.; Almeida, A.L.C.; Choi, E.-Y.; Wu, C.; Alonso, A.; et al. Cardiac Magnetic Resonance–Measured Left Atrial Volume and Function and Incident Atrial Fibrillation. *Circ. Cardiovasc. Imaging* 2016, 9. [CrossRef]